Background As the prevalence of hepatitis steatosis (HS) increases, the prevalence of HS
among those with chronic hepatitis B (CHB) may also be increasing but data on the effect of …

With the increasing incidence of obesity and metabolic syndrome worldwide, concomitant
nonalcoholic fatty liver disease (NAFLD) in patients with chronic hepatitis B (CHB) has …

Abstract Background Chronic hepatitis B (CHB) and fatty liver (FL) are common, natural
history data on concurrent FL and CHB (FL-CHB) are limited. This study aimed to evaluate …

Non-alcoholic fatty liver disease (NAFLD) and Hepatitis B virus infection (HBV) constitute
common chronic liver diseases with worldwide distribution. NAFLD burden is expected to …

Objective The relationship between chronic hepatitis B virus (HBV) infection and fatty liver in
patients remains unclear. Although high-fat diets-induced hepatic steatosis was proved to …

Chronic hepatitis B (CHB) virus infection is an important threat to global health despite the
administration of vaccines and the use of antiviral treatments. In recent years, as the …

Background & aims Nonalcoholic fatty liver disease (NAFLD) and chronic hepatitis B (CHB)
are common liver diseases. Concurrent NAFLD may affect antiviral treatment outcomes in …

Background/Aims The influence of hepatic steatosis (HS) on chronic hepatitis B (CHB) is
unclear. We evaluated the influence of the degree of HS, assessed using the controlled …

Metabolic dysfunction-associated fatty liver disease (MAFLD) and viral hepatitis due to
chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection are common liver …

Background The impact of hepatic steatosis (HS) on treatment response following nucleos
(t) ide analogue (NA) treatment for chronic hepatitis B (CHB) patients has not been clearly …